Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351536 | 0.93 | OPRM1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11309694 | 0.92 | OPRM1 (0.52) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11309707 | 0.92 | OPRM1 (0.52) | OPRD1OPRM1OPRK1 | |
| SCHEMBL7588235 | 0.89 | OPRD1 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL7588222 | 0.89 | OPRD1 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29406603 | 0.89 | CTSB (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31443264 | 0.87 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL9822626 | 0.87 | REN (0.69) | — | |
| SCHEMBL29351381 | 0.87 | OPRD1 (0.74) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29994086 | 0.86 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-0975661-A1 | THE PROLIFERATION OF CELL-INHIBITING PEPTIDE AND ITS USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998035983-A1 | THE PROLIFERATION OF CELL-INHIBITING PEPTIDE AND ITS USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | OPRD1 501/4885OPRM1 674/4885OPRK1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.